Sodium Chloride


Medefil, Inc.
Human Prescription Drug
NDC 64253-202
Sodium Chloride is a human prescription drug labeled by 'Medefil, Inc.'. National Drug Code (NDC) number for Sodium Chloride is 64253-202. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Sodium Chloride drug includes Sodium Chloride - 9 mg/mL . The currest status of Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 64253-202
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medefil, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SODIUM CHLORIDE - 9 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAMUSCULAR
INTRAVENOUS
SUBCUTANEOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Jan, 2012
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA202832
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Medefil, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:727820
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64253-202-3060 SYRINGE, PLASTIC in 1 BOX (64253-202-30) / 10 mL in 1 SYRINGE, PLASTIC13 Jan, 2012N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium chloride sodium chloride water sodium chloride sodium cation

Drug Interactions:

7 drug interactions some drugs or injections may be incompatible when combined with 0.9% sodium chloride. before sodium chloride injection, usp, 0.9% is used as a vehicle for the administration of a drug, the drug product manufacturer’s instructions or other specific references should be checked for any possible incompatibility with sodium chloride. consult with a pharmacist, if unsure of compatibility. • some drugs or injections may be incompatible when combined with 0.9% sodium chloride. • consult with a pharmacist, if unsure of compatibility ( 7 ).

Indications and Usage:

1 indications & usage sodium chloride injection, usp, 0.9% is indicated for: • dilution or dissolving the drugs for intravenous, intramuscular or subcutaneous injections ( 1.1 ). 1.1 dilution or dissolution of drugs sodium chloride injection, usp, 0.9% is indicated for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

Warnings and Cautions:

5 warnings and precautions • consult the drug product manufacturer’s instructions for choice of vehicle, appropriate dilution or volume for dissolving drugs to be injected including the route and rate of injection ( 5.1 ). • do not use sodium chloride injection, usp, 0.9% if the solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is damaged ( 5.1 ). • for single use only. discard unused portion ( 5.2 ). 5.1 general when used to dilute drug products, consult the drug product manufacturer’s instructions for choice of vehicle, appropriate dilution or volume for dissolving drugs to be injected including the route and rate of injection. inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration. do not use sodium chloride injection, usp 0.9% if the solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is dama
ged. 5.2 for single use only re-use of single-use product creates a potential risk to the user. contamination of product and/or limited functionality of the syringe may lead to injury, illness or death. discard any unused portion.

Dosage and Administration:

2 dosage & administration • volume of preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration recommended by the drug manufacturer ( 2.1 ). 2.1 recommended dosage the volume of preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration as recommended by the drug manufacturer. 2.2 instruction for administration solution and fluid path are sterile and non-pyrogenic if the tip cap is in place, syringe is intact and there is no evidence of leakage. use proper aseptic technique. inspect plastic wrapping. do not use if plastic wrapping is damaged or not intact. (figure 1) remove plastic packaging by tearing along perforation. (figure 2) do not use if, solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is damaged. (figure 3) with the tip cap of the syringe on, press the syring
e forward to properly activate the syringe. improper activation may difficult syringe use and/or may cause plunger rod separation. never draw back rod because the product may become contaminated. (figure 4) remove tip cap. hold the syringe unit upright and prime to expel any air bubble if present. (figure 5) syringe is now ready to use. use aseptic techniques for diluting or dissolving drugs, mix thoroughly and use according to the drug manufacturer’s label instructions. discard empty unit after use. discard any unused portion. do not reuse disposable syringes. 2.3 preparation and handling precautions before use check for any possible incompatibility with sodium chloride. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. do not administer unless solution is clear and seal is intact. do not store reconstituted solution or drugs for injection unless otherwise directed by the manufacturer of the solute. adding additives may be incompatible. do not use if, solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is damaged. do not freeze. exposure of pharmaceutical products to heat should be minimized. avoid excessive heat.

2.2 instruction for administration solution and fluid path are sterile and non-pyrogenic if the tip cap is in place, syringe is intact and there is no evidence of leakage. use proper aseptic technique. inspect plastic wrapping. do not use if plastic wrapping is damaged or not intact. (figure 1) remove plastic packaging by tearing along perforation. (figure 2) do not use if, solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe is damaged. (figure 3) with the tip cap of the syringe on, press the syringe forward to properly activate the syringe. improper activation may difficult syringe use and/or may cause plunger rod separation. never draw back rod because the product may become contaminated. (figure 4) remove tip cap. hold the syringe unit upright and prime to expel any air bubble if present. (figure 5) syringe is now ready to use. use aseptic techniques for diluting or dissolving drugs, mix thoroughly and use according to the drug manufacturer’s labe
l instructions. discard empty unit after use. discard any unused portion. do not reuse disposable syringes.

Dosage Forms and Strength:

3 dosage forms & strengths 10 ml fill in 12 ml syringe, 0.9% sodium chloride, usp, single use. • injection, 0.9%

Contraindications:

4 contraindications none • none

Adverse Reactions:

6 adverse reactions adverse reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include, but are not limited to, air embolization, febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and if possible, retrieve and save the remainder of unused vehicle for examination if deemed necessary. • reactions that may occur because of this solution, added drugs or the technique of reconstitution or administration include air embolization, febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasations ( 6 ). to report suspected adverse reaction
s, contact medefil, inc. at tel:1-630-682-4600 and http://www.medefilinc.com/ or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug Interactions:

7 drug interactions some drugs or injections may be incompatible when combined with 0.9% sodium chloride. before sodium chloride injection, usp, 0.9% is used as a vehicle for the administration of a drug, the drug product manufacturer’s instructions or other specific references should be checked for any possible incompatibility with sodium chloride. consult with a pharmacist, if unsure of compatibility. • some drugs or injections may be incompatible when combined with 0.9% sodium chloride. • consult with a pharmacist, if unsure of compatibility ( 7 ).

Description:

11 description sodium chloride injection, usp 0.9% is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. it contains no bacteriostatic antimicrobial agents or added buffer. the nominal ph is 5.5 (4.5 to 7.0). hydrochloric acid and/or sodium hydroxide may have been added for ph adjustment. sodium chloride injection, usp, 0.9% contains 9 g/l sodium chloride, usp (nacl) with a calculated osmolarity of approximately 308 mosmol/l. it contains 154 meq/l sodium and 154 meq/l chloride. the syringe component of sodium chloride injection, usp, 0.9% is manufactured with polypropylene and luer lock. the syringe is not made with natural rubber latex. the syringe is not made with dehp. this product contains no preservative. the syringes require no vapor barrier to maintain the proper drug concentration. the empirical formula for sodium chloride is nacl and the molecular weight is 58.44 g/mol. supplied as single use syringes.

Clinical Pharmacology:

12 clinical pharmacology sodium chloride in water dissociates to provide sodium (na+) and chloride (cl-) ions. these ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance. the small volume of fluid and amount of sodium chloride provided by sodium chloride injection, usp, 0.9% when used only as an isotonic vehicle for parenteral injection of drugs or for flushing of indwelling access devices, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in neonates and very small infants.

How Supplied:

16 how supplied/storage and handling the drug product is packaged in a clear plastic hypodermic syringe, which consists of a hypodermic barrel with luer lock, plunger stopper, plunger rod, and tip cap. the syringe is intended for single use and subsequent disposal. the 10 ml fill volume syringes are packaged individually in plastic pouches and 60 syringes are packaged into each dispensing box. dosage form product number ndc fill volume msd-0230 64253-202-30 10 ml fill in 12 ml syringe the above product is available in boxes of 30, 60 or 120 count each. storage and handling store at 25°c (77°f); excursions permitted to 15°-30°c (59° - 86°f). do not freeze.

Information for Patients:

17 patient counseling information 17.1 when using to dilute drug products, consult the drug product manufacturer’s instruction to confirm compatibility, appropriate dilution or volume for dissolving drugs including the route and rate of injection. inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration. do not use sodium chloride injection, usp 0.9% if the solution is discolored, cloudy, hazy, or contains a precipitate, or if the syringe damaged [ see warning and precautions, section 5.1 ]. 17.2 syringes are for single use only. discard unused portions and dispose of the unit in an appropriate sharps container. [ see warning and precaustions, section 5.2 ]. medefil, inc., 250 windy point drive, glendale heights, il 60139. prepared 10/2020 rev. 003

Package Label Principal Display Panel:

Package label.principal display panel manufactured by: medefil, inc., 250 windy point drive, glendale heights, il 60139. nda 202832 rev. 003 box-label syringe-label

Package insert_page 1 and 2 package insert_page 1 package insert_page 2


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.